Medivation Inc. (NASDAQ:MDVN) stock dropped 7% during pre-market hours today, after the Food and Drug Administration (FDA) placed MDV9300 on a partial clinical hold, as the company concluded that the previously-provided mechanism of action is not appropriate. It is now working to determine the adequate pathway for future. At present, the stock is trading down 1.80% at $36.97, as of 8:48 AM EST.
